Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: US FDA Accepts Ertugliflozin, Extends Reviews Of Abaloparatide, New Keytruda Claim

Mar 12 2017

• By Bridget Silverman

Related Content

With VERTIS SITA2 On Board, Merck Eyes Broad Initial Approval For Ertugliflozin

Sep 16 2016

Keeping Track: Ilaris Adds Three Rare Disease Claims; Sirukumab Submitted; Exondys 51's Surprising Approval

Sep 23 2016

Keeping Track: Immuno-Oncologics And Abuse-Deterrent Opioids Take Center Stage (Again); Jardiance CV Claim Approved

Dec 04 2016

Keeping Track: Xermelo, Odactra, Noctiva Approved; Second Submissions For Avelumab And Deutetrabenazine

Mar 05 2017

Keeping Track: Arymo ER Approved, Parsabiv Returns, Merck Surprises With Keytruda Chemo Combo Submission

Jan 14 2017

Keeping Track: FDA Rejects Mealtime Insulin, Antihistamine; Misses Goal For Another Opioid

Oct 14 2016

ADA: Diabetes Duo Merck & Pfizer Report Positive PhIII Data For Investigational SGLT-2

Jun 11 2016

AstraZeneca Diabetes Combo Needs More Clinical Data, FDA Says

Oct 16 2015

Jardiance's Label Expansion Will Change Diabetes Management

Dec 05 2016

Will Radius Health's Abaloparatide Data Do The Trick In Osteoporosis?

Aug 19 2016

Related Companies

Radius Health, Inc.

Merck & Co., Inc.

Pfizer Inc.

Nicox S.A.

PolyPid Ltd.

Boehringer Ingelheim GmbH

Eli Lilly and Company

AstraZeneca PLC

Boehringer Ingelheim GmbH

Eli Lilly and Company

PTC Therapeutics, Inc.

Keryx Biopharmaceuticals Inc.

Alexion Pharmaceuticals Inc.

Additional Topics

United States Approvals Review Pathway Regulation BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window